Eaton, John K. http://orcid.org/0000-0003-4633-5546
Furst, Laura
Ruberto, Richard A.
Moosmayer, Dieter
Hilpmann, André
Ryan, Matthew J.
Zimmermann, Katja
Cai, Luke L. http://orcid.org/0000-0003-4204-1938
Niehues, Michael
Badock, Volker
Kramm, Anneke
Chen, Sixun
Hillig, Roman C.
Clemons, Paul A. http://orcid.org/0000-0002-1800-5112
Gradl, Stefan
Montagnon, Claire
Lazarski, Kiel E.
Christian, Sven
Bajrami, Besnik
Neuhaus, Roland
Eheim, Ashley L.
Viswanathan, Vasanthi S. http://orcid.org/0000-0001-9878-3629
Schreiber, Stuart L. http://orcid.org/0000-0003-1922-7558
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R35GM127045))
Article History
Received: 20 August 2019
Accepted: 13 February 2020
First Online: 30 March 2020
Competing interests
: S.L.S. serves on the Board of Directors of the Genomics Institute of the Novartis Research Foundation (“GNF”); is a shareholder and serves on the Board of Directors of Jnana Therapeutics; is a shareholder of Forma Therapeutics; is a shareholder and advises Kojin Therapeutics, Kisbee Therapeutics, Decibel Therapeutics and Eikonizo Therapeutics; serves on the Scientific Advisory Boards of Eisai Co., Ltd., Ono Pharma Foundation, Exo Therapeutics, and F-Prime Capital Partners; and is a Novartis Faculty Scholar. P.A.C. is an advisor to Pfizer, Inc. D.M., A.H., K.Z., M.N., V.B., R.C.H., S.G., S. Christian, R.N. and A.L.E. are employed by Bayer AG.